CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1200 participants.

Also called NCT06283888

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06283888
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06283888. Randomized; no masking; primary purpose treatment. Start 2024-04-01 (anticipated); primary completion 2028-04-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention
Condition
ACS - Acute Coronary Syndrome
Condition
CYP2C19 Polymorphism
Intervention (Drug)
CYP2C19 Genotype Guided DAPT
Intervention (Drug)
Conventional DAPT
Lead sponsor
Zunyi Medical College (class: other)

Record details

Record id
cardio:ct-nct06283888
Content hash
60d5404c0de1439dc6ec47f31aa9e35ffd7ebcc14246ed63c70ea2643f9509b8